(Q33224640)

English

Antidiabetic potential of two novel fatty acid derivatised, N-terminally modified analogues of glucose-dependent insulinotropic polypeptide (GIP): N-AcGIP(LysPAL16) and N-AcGIP(LysPAL37).

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

24 July 2017

Antidiabetic potential of two novel fatty acid derivatised, N-terminally modified analogues of glucose-dependent insulinotropic polypeptide (GIP): N-AcGIP(LysPAL16) and N-AcGIP(LysPAL37). (English)

1 reference

Europe PubMed Central

24 July 2017

0 references

Victor A. Gault

object named as

Victor A Gault

2

0 references

object named as

Nigel Irwin

1

0 references

object named as

Peter R Flatt

7

0 references

Clifford J Bailey

object named as

Clifford J Bailey

6

1 reference

ORCID Public Data File 2021

Patrick Harriott

5

object named as

Patrick Harriott

1 reference

Europe PubMed Central

24 July 2017

author name string

Brian D Green

3

1 reference

Europe PubMed Central

24 July 2017

Brett Greer

4

1 reference

Europe PubMed Central

24 July 2017

Finbarr P M O'Harte

8

1 reference

Europe PubMed Central

24 July 2017

publication date

1 July 2005

1 reference

Europe PubMed Central

24 July 2017

Biological Chemistry

1 reference

Europe PubMed Central

24 July 2017

386

1 reference

Europe PubMed Central

24 July 2017

7

1 reference

Europe PubMed Central

24 July 2017

679-687

1 reference

Europe PubMed Central

24 July 2017

The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men.

1 reference

https://api.crossref.org/works/10.1515%2FBC.2005.079

21 January 2018

Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1515%2FBC.2005.079

21 January 2018

The entero-insular axis in type 2 diabetes--incretins as therapeutic agents

1 reference

https://api.crossref.org/works/10.1515%2FBC.2005.079

21 January 2018

Enhancing Incretin Action for the Treatment of Type 2 Diabetes

1 reference

https://api.crossref.org/works/10.1515%2FBC.2005.079

21 January 2018

Glucose-dependent insulinotropic polypeptide promotes beta-(INS-1) cell survival via cyclic adenosine monophosphate-mediated caspase-3 inhibition and regulation of p38 mitogen-activated protein kinase.

1 reference

https://api.crossref.org/works/10.1515%2FBC.2005.079

21 January 2018

Evidence that the major degradation product of glucose-dependent insulinotropic polypeptide, GIP(3-42), is a GIP receptor antagonist in vivo

1 reference

https://api.crossref.org/works/10.1515%2FBC.2005.079

21 January 2018

Enhanced cAMP generation and insulin-releasing potency of two novel Tyr1-modified enzyme-resistant forms of glucose-dependent insulinotropic polypeptide is associated with significant antihyperglycaemic activity in spontaneous obesity-diabetes

1 reference

https://api.crossref.org/works/10.1515%2FBC.2005.079

21 January 2018

DPP IV resistance and insulin releasing activity of a novel di-substituted analogue of glucose-dependent insulinotropic polypeptide, (Ser2-Asp13)GIP.

1 reference

https://api.crossref.org/works/10.1515%2FBC.2005.079

21 January 2018

Cyclic AMP production and insulin releasing activity of synthetic fragment peptides of glucose-dependent insulinotropic polypeptide.

1 reference

https://api.crossref.org/works/10.1515%2FBC.2005.079

21 January 2018

Glucose-dependent insulinotropic polypeptide analogues and their therapeutic potential for the treatment of obesity-diabetes.

1 reference

https://api.crossref.org/works/10.1515%2FBC.2005.079

21 January 2018

Glucose-dependent insulinotropic polypeptide (GIP): anti-diabetic and anti-obesity potential?

1 reference

https://api.crossref.org/works/10.1515%2FBC.2005.079

21 January 2018

Improved biological activity of Gly2- and Ser2-substituted analogues of glucose-dependent insulinotrophic polypeptide

1 reference

https://api.crossref.org/works/10.1515%2FBC.2005.079

21 January 2018

Degradation, receptor binding, insulin secreting and antihyperglycaemic actions of palmitate-derivatised native and Ala8-substituted GLP-1 analogues.

1 reference

https://api.crossref.org/works/10.1515%2FBC.2005.079

21 January 2018

Cloning, functional expression, and chromosomal localization of the human pancreatic islet glucose-dependent insulinotropic polypeptide receptor

1 reference

https://api.crossref.org/works/10.1515%2FBC.2005.079

21 January 2018

Identification of a bioactive domain in the amino-terminus of glucose-dependent insulinotropic polypeptide (GIP).

1 reference

https://api.crossref.org/works/10.1515%2FBC.2005.079

21 January 2018

Dipeptidyl peptidase IV-resistant [D-Ala(2)]glucose-dependent insulinotropic polypeptide (GIP) improves glucose tolerance in normal and obese diabetic rats

1 reference

https://api.crossref.org/works/10.1515%2FBC.2005.079

21 January 2018

Gastric inhibitory polypeptide analogues: do they have a therapeutic role in diabetes mellitus similar to that of glucagon-like Peptide-1?

1 reference

https://api.crossref.org/works/10.1515%2FBC.2005.079

21 January 2018

Development and characterization of a glucagon-like peptide 1-albumin conjugate: the ability to activate the glucagon-like peptide 1 receptor in vivo

1 reference

https://api.crossref.org/works/10.1515%2FBC.2005.079

21 January 2018

Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration

1 reference

https://api.crossref.org/works/10.1515%2FBC.2005.079

21 January 2018

Structure-function analysis of a series of novel GIP analogues containing different helical length linkers

1 reference

https://api.crossref.org/works/10.1515%2FBC.2005.079

21 January 2018

Gastric inhibitory polypeptide: the neglected incretin revisited

1 reference

https://api.crossref.org/works/10.1515%2FBC.2005.079

21 January 2018

Gastric inhibitory polypeptide does not inhibit gastric emptying in humans

1 reference

https://api.crossref.org/works/10.1515%2FBC.2005.079

21 January 2018

Secretion, degradation, and elimination of glucagon-like peptide 1 and gastric inhibitory polypeptide in patients with chronic renal insufficiency and healthy control subjects

1 reference

https://api.crossref.org/works/10.1515%2FBC.2005.079

21 January 2018

Stimulation of insulin secretion by intravenous bolus injection and continuous infusion of gastric inhibitory polypeptide in patients with type 2 diabetes and healthy control subjects.

1 reference

https://api.crossref.org/works/10.1515%2FBC.2005.079

21 January 2018

Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1515%2FBC.2005.079

21 January 2018

NH2-terminally modified gastric inhibitory polypeptide exhibits amino-peptidase resistance and enhanced antihyperglycemic activity.

1 reference

https://api.crossref.org/works/10.1515%2FBC.2005.079

21 January 2018

Improved stability, insulin-releasing activity and antidiabetic potential of two novel N-terminal analogues of gastric inhibitory polypeptide: N-acetyl-GIP and pGlu-GIP.

1 reference

https://api.crossref.org/works/10.1515%2FBC.2005.079

21 January 2018

Dipeptidyl peptidase IV inhibitor treatment stimulates beta-cell survival and islet neogenesis in streptozotocin-induced diabetic rats.

1 reference

https://api.crossref.org/works/10.1515%2FBC.2005.079

21 January 2018

Glucose-dependent insulinotropic polypeptide is a growth factor for beta (INS-1) cells by pleiotropic signaling

1 reference

https://api.crossref.org/works/10.1515%2FBC.2005.079

21 January 2018

Mechanisms of mitogenic and anti-apoptotic signaling by glucose-dependent insulinotropic polypeptide in beta(INS-1)-cells

1 reference

https://api.crossref.org/works/10.1515%2FBC.2005.079

21 January 2018

GIP regulates glucose transporters, hexokinases, and glucose-induced insulin secretion in RIN 1046-38 cells

1 reference

https://api.crossref.org/works/10.1515%2FBC.2005.079

21 January 2018

GIP biology and fat metabolism

1 reference

https://api.crossref.org/works/10.1515%2FBC.2005.079

21 January 2018

The effects of glucose-dependent insulinotropic polypeptide infused at physiological concentrations in normal subjects and Type 2 (non-insulin-dependent) diabetic patients on glucose tolerance and B-cell secretion

1 reference

https://api.crossref.org/works/10.1515%2FBC.2005.079

21 January 2018

Identifiers

10.1515/BC.2005.079

1 reference

Europe PubMed Central

24 July 2017

1 reference

Europe PubMed Central

24 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33224640&oldid=1859105245"